The efficacy and safety of pazopanib were assessed in 156 Japanese patients with relapsed soft-tissue sarcoma (STS). This was a retrospective study based on postmarketing surveillance data. To be included in this study, patients’ primary tumor had to arise from the extremities or trunk, and they had to receive pazopanib for unresectable local recurrence and/or a metastatic lesion. Patients received pazopanib with the objective of treating local recurrence (n = 20), metastasis (n = 104), or both (n = 32). Their median age was 54 years. The median treatment duration was 28.7 weeks, and the average dose intensity was 609 mg. Adverse events occurred in 81% of patients. In addition to hypertension and liver dysfunction, unique toxicities of pneumothorax and thrombocytopenia were observed. Among 156 patients, evaluable tumor response occurred in 80%. Thirteen patients achieved a partial response (PR) and 74 achieved stable disease (SD). SD was maintained for a period of 6 months in 32 patients (long SD). PR or long SD was achieved in patients with alveolar soft part sarcoma (78%), leiomyosarcoma (LMS; 44%), and synovial sarcoma (SS; 44%). Median progression-free survival (PFS) for all patients was 15.4 weeks. Median PFS for patients with LMS, SS, undifferentiated pleomorphic sarcoma (UPS), and liposarcoma (LPS) was 18.6 weeks, 16.4 weeks, 15.3 weeks, and 8 weeks, respectively. Median overall survival (OS) for all patients was 11.2 months. Median OS for patients with LMS, SS, UPS, and LPS was 20.1 months, 10.6 months, 9.5 months, and 7.3 months, respectively. Nakamura T, et al. CTOS 2016. Abstract 2541028. P2 Poster 112.